HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TLX
Telix Pharmaceuticals Limited
There isn't enough reported data to score TLX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TLX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Weak |
TLX's profitability and balance sheet are currently weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TLX PE Valuation
TLX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TLX Forward outlook
There aren't enough analyst estimates for TLX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TLX Earnings Per Share
TLX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $803.8M | +50% |
| Q4 2024 | $536.1M | +178% |
| Q4 2023 | $192.8M | +107% |
| Q2 2023 | $151.2M | +818% |
| Q4 2022 | $93.1M | +2803% |
| Q2 2022 | $16.5M | +726% |
| Q4 2021 | $3.2M | +30% |
| Q2 2021 | $2M | +81% |
TLX has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 3.7% | +11 points |
| Q4 2024 | 10% | +275 points |
| Q4 2023 | -5.5% | +1060 points |
| Q2 2023 | 14% | +1100 points |
| Q4 2022 | -7.1% | +801 points |
| Q2 2022 | -264% | +987 points |
| Q4 2021 | -1065% | +378 points |
| Q2 2021 | -1086% | -195 points |
TLX's operating margin was 3.7% last quarter, up 11 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
TLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$43M | -319% |
| Q4 2024 | $19.7M | +626% |
| Q4 2023 | $2.7M | +$8.5M |
| Q2 2023 | $7M | +$49.9M |
| Q4 2022 | -$5.8M | +$15.9M |
| Q2 2022 | -$42.8M | -$23M |
| Q4 2021 | -$21.7M | -255% |
| Q2 2021 | -$19.8M | -$7.1M |
TLX has burned cash in most quarters: −$14M over the past year, against −$90M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TLX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -7.3M shares |
| 1 year | +6.8% | +21.5M shares |
| 3 years | +63% | +131M shares |
| 5 years | +774% | +299M shares |
| Available history | +774% | +299M shares |
TLX has 338M diluted shares, up 6.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over TLX on leverage, with a lower net debt burden relative to earnings.
TLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 5.1x | High |
| Q4 2024 | -1.6x | Net Cash |
TLX's net debt is about 5.1 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 10.8 | Oversold |
TLX's weekly RSI is 44 (neutral) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TLX PE vs Healthcare Sector
| Metric | TLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TLX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
TLX has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus TLX above 0 of 4.
TLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 7.7% below |
| 20 week MA | $10.8 | 13% below |
| 50 week MA | $9.66 | 3.1% below |
| 100 week MA | $12.1 | 23% below |
TLX is in a downtrend: it's below all four of its weekly moving averages, and 23% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $14.9 | $15.6 | +5.1% |
| 2025 | $15.6 | $8.03 | -49% |
| 2026 YTD | $8.03 | $9.36 | +17% |
TLX has the edge over HIMS on returns for 2026, with the stronger performance.